Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.
Steven Yip(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center), Naveen S. Basappa, Hao‐Wen Sim(The University of Sydney), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Ravindran Kanesvaran(University of Ioannina), Toni K. Choueiri(Harvard University), Anil Kapoor(People’s University), Alex H.C. Wong(University of Alberta), D. Scott Ernst, Lori Wood(Dalhousie University), Raphael Brandão Moreira(Dana-Farber Cancer Institute), Simon Fu(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Christina M. Canil(University of Ottawa), Sandy Srinivas(Stanford University), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Camillo Porta(University of Pavia)
Cited by 12
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k